Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 3Unknown 1Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1Plasma cell 1

Conditions

Sarcoma 727Glioblastoma 354Gliosarcoma 341Brain Neoplasms 254Central Nervous System Neoplasms 223Astrocytoma 204Osteosarcoma 202Gastrointestinal Stromal Tumors 176Dendritic Cell Sarcoma, Interdigitating 174Glioma 165Lymphoma 163Burkitt Lymphoma 162Precursor Cell Lymphoblastic Leukemia-Lymphoma 158Neoplasms 155Lymphoma, Non-Hodgkin 151Oligodendroglioma 147Recurrence 138Lymphoma, Large B-Cell, Diffuse 133Neuroblastoma 130Lymphoma, Follicular 127Breast Neoplasms 121Leukemia, Lymphocytic, Chronic, B-Cell 120Lymphoma, Mantle-Cell 119Leukemia 116Lymphoma, B-Cell, Marginal Zone 113Lymphoma, Large-Cell, Immunoblastic 112Rhabdomyosarcoma 111Hodgkin Disease 110Bone Neoplasms 109Sarcoma, Kaposi 102

Interventions

tocilizumab 1Zidovudine 1Valganciclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Castleman Disease × Sarcoma × Clear all
NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
8 enrolled 18 charts
LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon âš¡